191 related articles for article (PubMed ID: 19550402)
1. Assessment of anthracycline-induced cardiotoxicity with electrocardiography.
Horacek JM; Jakl M; Horackova J; Pudil R; Jebavy L; Maly J
Exp Oncol; 2009 Jun; 31(2):115-7. PubMed ID: 19550402
[TBL] [Abstract][Full Text] [Related]
2. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines.
Pudil R; Horacek JM; Strasova A; Jebavy L; Vojacek J
Exp Oncol; 2008 Jun; 30(2):160-2. PubMed ID: 18566583
[TBL] [Abstract][Full Text] [Related]
4. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia.
Horacek JM; Tichy M; Jebavy L; Pudil R; Ulrychova M; Maly J
Exp Oncol; 2008 Jun; 30(2):157-9. PubMed ID: 18566582
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline induced cardiotoxicity in adult cancer patients: a prospective cohort study from a specialized oncology treatment centre in Uganda.
Kibudde S; Mondo CK; Kibirige D; Walusansa V; Orem J
Afr Health Sci; 2019 Mar; 19(1):1647-1656. PubMed ID: 31148994
[TBL] [Abstract][Full Text] [Related]
6. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy.
Gupta M; Thaler HT; Friedman D; Steinherz L
Pediatr Hematol Oncol; 2002 Dec; 19(8):533-42. PubMed ID: 12487828
[TBL] [Abstract][Full Text] [Related]
7. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
Mortensen SA; Aabo K; Jonsson T; Baandrup U
Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718
[TBL] [Abstract][Full Text] [Related]
8. The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose.
Buckley NA; Chevalier S; Leditschke IA; O'Connell DL; Leitch J; Pond SM
Crit Care; 2003 Oct; 7(5):R101-7. PubMed ID: 12974977
[TBL] [Abstract][Full Text] [Related]
9. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
[TBL] [Abstract][Full Text] [Related]
10. [High-resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children].
Mladosievicová B; Foltinová A; Bernadic M; Petrásová H; Hulín I
Bratisl Lek Listy; 1996 May; 97(5):289-97. PubMed ID: 8705327
[TBL] [Abstract][Full Text] [Related]
11. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma.
Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Nousiainen T; Hartikainen J
Clin Physiol Funct Imaging; 2010 May; 30(3):175-80. PubMed ID: 20132128
[TBL] [Abstract][Full Text] [Related]
12. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.
Chen C; Heusch A; Donner B; Janssen G; Göbel U; Schmidt KG
Klin Padiatr; 2009; 221(3):162-6. PubMed ID: 19437364
[TBL] [Abstract][Full Text] [Related]
13. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
14. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
15. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
16. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic optimization of interventricular delay in cardiac resynchronization therapy: a simple method to optimize the device.
Vidal B; Tamborero D; Mont L; Sitges M; Delgado V; Berruezo A; Díaz-Infante E; Tolosana JM; Paré C; Brugada J
J Cardiovasc Electrophysiol; 2007 Dec; 18(12):1252-7. PubMed ID: 17916140
[TBL] [Abstract][Full Text] [Related]
19. Acute electrocardiographic changes induced by amsacrine.
Shinar E; Hasin Y
Cancer Treat Rep; 1984 Sep; 68(9):1169-72. PubMed ID: 6592038
[TBL] [Abstract][Full Text] [Related]
20. Signal-averaged electrocardiography in children with anthracycline-induced cardiomyopathy.
Vaksmann G; Gutierrez R; Duhamel A; Nelken B; Francart C; Kouakam C; Mazingue F; Rey C
Pediatr Cardiol; 2001; 22(6):494-8. PubMed ID: 11894153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
